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We present ﬁve cases of saddle pulmonary embo-
lism with normal right ventricular systolic func-
tion and discuss the management option of this
condition.
Introduction
Management of saddle pulmonary embolism (PE)
in haemodynamically stable patients with normal
right ventricular (RV) function is unclear.
Thrombolytic agents are indicated in haemody-
namically unstable patients with PE.
1 RV dysfunc-
tion has also been used as an indication for
surgical embolectomy in normotensive patients
with PE.
2 Embolized thrombus burden, although
intuitively related both to haemodynamic status
and RV dysfunction, has not been consistently
linked to prognosis. In particular, an unsettled
issue is the prognosis and beneﬁt of aggressive
treatment including thrombolytic agents in hemo-
dynamically stable patients with large pulmonary
embolism in the main pulmonary artery (saddle
PE) who have no evidence of RV dysfunction.
We discuss the management of ﬁve patients with
saddle pulmonary embolism who were haemody-
namically stable and showed normal RV function.
Case histories
Case 1
A 66-year-old woman undergoing chemotherapy
forbilateralbreast cancerpresentedwithdyspnoea.
On admission, her blood pressure (BP) was 169/
99 mmHg, oxygen (O2) saturation was 93% on
roomair(RA)withnosignsofheartfailure.Atrans-
thoracic echocardiogram (TTE) showed normal RV
size and function with normal left ventricular
ejectionfraction(LVEF)at55–60%.Computedtomo-
graphic (CT) angiogram scan showed a saddle
embolus partially extending in both pulmonary
arteries. A Doppler ultrasound of the lowerextremi-
ties showed a deep vein thrombosis of the left popli-
teal vein. Unfractionated heparin (UFH) was given
and an inferior vena cava (IVC) ﬁlter was deployed.
The patient was discharged home on warfarin. She
died 8 months later due to progression of cancer.
Case 2
A 62-year-old woman who underwent surgery
for malignant meningioma presented with chest
pain and dyspnoea. On admission her BP was
110/61 mmHg, O2 saturation of 97% on 4 L of sup-
plemental O2 and showed no signs of instability.
She was diagnosed with lower extremity deep
venous thrombosis one week earlier and treated
with UFH and warfarin. However, due to an elev-
ated international normalized ratio (INR) of 5.73
and partial thromboplastin time >100, warfarin
was withheld. A TTE showed normal RV size and
function with an estimated right ventricular systolic
pressure (RVSP) at 25 mmHg, and normal LVEF
at 55–60%. A 12-lead electrocardiogram (ECG)
showed sinus tachycardia at 101 beats per minute
(bpm). A CT scan of the lungs showed saddle pul-
monary embolus. Low molecular weight heparin
(LMWH)wasgivenandanIVCﬁlterwasdeployed.
The patient was discharged home on LMWH. She
died 1 month later due to progression of cancer.
Case 3
A 37-year-old man who was receiving treatment
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1dyspnoea. On examination his BP was 100/
70 mmHg with no signs of RV failure. A 12-lead
ECG showed sinus tachycardia at 107 bpm and a
new right bundle branch block. A TTE showed
normal RV size and function with an estimated
RVSP at 30–40 mmHg and normal LVEF at
60–65%. A CT scan showed saddle embolus
extending into the right and left pulmonary
artery (Figure 1). Patient received one dose of
tissue plasminogen activator (TPA) and was
started on LMWH and IVC ﬁlter was placed.
After a suspected episode of heparin-induced
thrombocytopenia, the patient was placed on
lepirudin. The patient was eventually discharged
home on warfarin. A follow-up CT scan showed
progressive reduction in the size of the embolus.
The patient died 5 months later due to progression
of cancer.
Case 4
A 65-year-old man who was undergoing che-
motherapy for glioblastoma multiforme
presented with dyspnoea. On examination, his
BP was 127/97 mmHg, O2 saturation was 98% on
room air and appeared stable. A 12-lead ECG
was normal. A TTE showed normal RV size and
function, with mildly increased RVSP at 30–
40 mmHg and a normal LVEF at 55–60%. A CT
scan showed saddle embolus and multiple
smaller peripheral emboli. The patient was
started on LMWH and was discharged home.
Patient died 3 months later due to progression of
brain tumor.
Case 5
A 71-year-old man with a recent compression
fracture due to multiple myeloma presented with
chest pain and dyspnoea. He had been diagnosed
with deep vein thrombosis 2 months earlier and
had been receiving warfarin. The INR was 1.12
when he presented to the hospital. On admission
his BP was 135/81 mmHg and showed no signs
of heart failure. An arterial blood gas showed a
pH of 7.46, PO2 of 56 mmHg and a PCO2 of
31 mmHg. A TTE showed normal RV size and
function with mild pulmonary hypertension
(RVSP at 30–40 mmHg) and normal LVEF at 60–
65%. CT scan showed a large saddle embolus
extending into right and left pulmonary artery.
The patient was started on UFH and TPA. TPA
was discontinued due to abrupt onset of chest
pain during its administration. A repeat CT scan
after 2 days showed a decrease in size of the
embolus. The patient was later discharged home
on warfarin. The patient is still alive 7 years after
the episode of saddle PE.
Discussion
PE is a leading cause of death among hospitalized
patients.
3 Mortality in PE is related to RV dysfunc-
tion and hemodynamic instability. Thromboem-
bolic obstruction of the PA and vasospasm due to
hypoxia increases the pulmonary vascular resist-
ance and leads to RV pressure overload. This in
turn causes RV dilatation, hypokinesis or even
failure.
4 Decrease in RV output reduces left atrial
ﬁlling, which in turn compromises LV preload. In
addition, RV enlargement causes leftward shift of
interventricular septum during diastole leading to
additional impairment in left ventricular ﬁlling
and further decrease in cardiac output.
4
The largestPE,termed saddlepulmonaryembo-
lism is deﬁned as thromboemboli at the bifurcation
of the pulmonary trunk with or without extension
into the left and/or right main pulmonary
arteries.
5,6 While saddle PE may usually cause RV
dysfunction, up to 45% of stable patients with
saddle PE have normal RV function.
6 Even in the
absence of RV dysfunction, saddle PE is associated
with a higher one year mortality, when compared
to large non-saddle PE.
6
RV dysfunction is a major determinant of
prognosis in both hemodynamically stable and
Figure 1
Saddle pulmonary embolus
J R Soc Med Sh Rep 2010;1:12. DOI 10.1258/shorts.2009.090357
Journal of the Royal Society of Medicine Short Reports
2unstable patients with PE.
7–9Short-term mortality
is high in normotensive patients with RV dysfunc-
tion than in patients with normal RV function.
7
Furthermore, one-year mortality in patients with
PE and RV strain at presentation was 13% and
1.3% in those without RV strain.
8 In another
study there was two-fold increase in mortality in
patients with right ventricular hypokinesia.
9
The treatments for saddle PE beyond anti-
coagulants may include thrombolytic therapy
(systemic and intra-luminal via catheter) and sur-
gical embolectomy (open and percutaneous).
6
Thrombolytics are recommended in patients with
PE and hemodynamic instability.
1 The data for
thrombolytic therapyeven in this subset of patients
are sparse, with only one randomized trial of eight
patients in cardiogenic shock showing mortality
beneﬁt with streptokinase.
10 In patients with PE,
thrombolytics improve RV function.
11 In a case of
saddle PE, thrombolytics has been reported to
improve and normalize RV function.
12 Whether
this will result in mortality beneﬁt is unknown, as
there are no randomized trials of thrombolytics in
saddle PE. The limitations of published studies
onsaddlePEaresmallsamplesizeandinconsistent
management strategies. The total number of
patients included in the studies of saddle PE has
ranged from 17 to 22 patients.
6,13,14
Although thrombolytics was used in two patients
in our series, long-term prognosis could not be
assessed as four of them died within a few months
due to progression of cancer. Whether thrombolytics
or pharmacological reduction of pulmonary hyper-
tension in patients with saddle PE would improve
late mortality needs further exploration.
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